Asset Comparison and Correlation

Given investment horizon of 30 days, Nektar Therapeutics is expected to under-perform the Insite. But the stock apears to be less risky and, when comparing its historical volatility, Nektar Therapeutics is 1.62 times less risky than Insite. The stock trades about -0.17 of its potential returns per unit of risk. The Insite Vision Inc. is currently generating about -0.01 of returns per unit of risk over similar time horizon. If you would invest 37.00 in Insite Vision Inc. on April 26, 2012 and sell it today you would lose (2.00) from holding Insite Vision Inc. or give up 5.41% of portfolio value over 30 days.